Dachaigh › Cancer briste triple-negative › New York › New York City
Sgrùdaidhean clionaigeach Cancer briste triple-negative ann an New York City, NY
Tha 31 sgrùdaidhean airson Cancer briste triple-negative a’ lorg phàirtichean aig làraichean ann agus timcheall air New York City (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
A’ fastadhÌre 1
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- Icahn School of Medicine at Mount Sinai, New York
- agus 2 a bharrachd
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A’ fastadhÌre 1/2
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
A’ fastadhÌre 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Study of AVZO-021 in Patients With Advanced Solid Tumors
A’ fastadhÌre 1/2
- Avenzo Therapeutics Recruiting Site, New York
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
A’ fastadhSgrùdadh amharc
- NYU Langone Medical Center, New York
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
A’ fastadhÌre 3
- Laura and Isaac Perlmutter Cancer Center ( Site 0003), New York
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
A’ fastadhÌre 3
- The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0135), New York
- Icahn School of Medicine at Mount Sinai ( Site 0123), New York
- Memorial Sloan Kettering Cancer Center ( Site 0067), New York
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
A’ fastadhÌre 1
- Memorial Sloan Kettering Cancer Center Head Neck Services, New York
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
A’ fastadhÌre 1
- Icahn School of Medicine at Mt. Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
A’ fastadhÌre 1
- Memorial Sloan Kettering Cancer Center (All protocol activites), New York
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
A’ fastadhÌre 1/2
- Mount Sinai, New York
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
A’ fastadhÌre 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
A’ fastadhÌre 2
- NYP/Weill Cornell Medical Center, New York
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
A’ fastadhÌre 3
- Laura and Isaac Perlmutter Cancer Canter, New York
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
A’ fastadhÌre 1
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer
A’ fastadhÌre 2
- Memorial Sloan-Kettering Cancer Center (All Protocol Activities), New York
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
A’ fastadhÌre 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
A’ fastadhÌre 2/3
- Memorial Sloan Kettering Cancer Center, New York
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Memorial Sloan Kettering Cancer Center 53rd street., New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
A’ fastadhÌre 1/2
- New York University Langone Health, New York
- ICHAN School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of LY4175408 in Participants With Advanced Cancer
A’ fastadhÌre 1
- Columbia University, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
A’ fastadhÌre 1
- New York Medicine-New York-Presbyterian Hospital, New York
- Montefiore Medical Center - Montefiore Hospital, New York
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
A’ fastadhÌre 1/2
- Memorial Sloan Kettering Cancer Center, New York
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
A’ fastadhÌre 1 tràth
- Mount Sinai Health System, New York
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
A’ fastadhÌre 2
- Laura and Isaac Perlmutter Cancer Center / NYU Langone Health, New York
- Columbia University Medical Center, New York
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
A’ fastadhÌre 1/2
- NYU Langone perimutter Cancer Center, New York
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
A’ fastadhÌre 1
- Memorial Sloan Kettering Cancer Center, New York
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
A’ fastadhÌre 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
A’ fastadhÌre 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
A’ fastadhÌre 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
A’ fastadhÌre 1/2
- NYU Langone Health, New York
Sgrùdaidhean Cancer briste triple-negative ann am bailtean eile
- Houston, TX42 sgrùdaidhean
- Nashville, TN28 sgrùdaidhean
- Los Angeles, CA27 sgrùdaidhean
- Boston, MA26 sgrùdaidhean
- San Antonio, TX23 sgrùdaidhean
- St. Louis, MO21 sgrùdaidhean
- Arlington, VA20 sgrùdaidhean
- Atlanta, GA20 sgrùdaidhean
- Dallas, TX18 sgrùdaidhean
- Chicago, IL16 sgrùdaidhean
- Columbus, OH16 sgrùdaidhean
- Grand Rapids, MI15 sgrùdaidhean
Sgrùdaidhean eile ann an New York City
- Aillse a' bhroilleach136 sgrùdaidhean
- Aillse Sgamhain Neo-chealla-beag121 sgrùdaidhean
- Aillse (gach seòrsa)109 sgrùdaidhean
- Aillse Prostata103 sgrùdaidhean
- Ailse metastatach93 sgrùdaidhean
- Aillse colorectal78 sgrùdaidhean
- Cancer Ovarian69 sgrùdaidhean
- Ailseachadh nan Sgamhan60 sgrùdaidhean
- Myeloma iomaill60 sgrùdaidhean
- Cancer Pancreatic60 sgrùdaidhean
- Ailse Endometrial52 sgrùdaidhean
- Leukemia myeloid geur51 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.